NCT06899061 2026-03-03
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
17 trialsNCT07211880 2025-10-08
Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study
Zero Helicobacter IGAN Network
Phase NA Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07076914 2025-07-22
PPI-PROTECT
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Not yet recruiting
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT02407119 2023-11-09
Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD
National Cancer Center, Korea
Phase 3 Active not recruiting
NCT05930119 2023-09-06
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
Hutchmed
Phase 1 Completed
NCT05571787 2023-02-23
HMPL-523 Food Effect and Proton Pump Inhibitor Study
Hutchmed
Phase 1 Completed
NCT04697186 2023-01-31
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
Xijing Hospital of Digestive Diseases
Phase 4 Completed
NCT04944771 2022-05-09
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT04564040 2020-12-29
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
AstraZeneca
Phase 1 Completed
NCT04254471 2020-02-05
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Haihe Biopharma Co., Ltd.
Phase 2/3 Unknown
NCT02747797 2018-08-02
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
University of California, San Diego
Phase 2 Withdrawn
NCT03260179 2017-08-24
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT03117101 2017-04-17
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT02149914 2014-11-20
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
Taichung Tzu Chi Hospital
Phase NA Unknown
NCT00844675 2012-10-18
Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection
The Catholic University of Korea
Phase 4 Completed